HOPE
2000
Heart Outcomes Prevention Evaluation
In 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.
Result
Efficacy: MI, stroke, or death from cardiovascular causesRR 0.78 (95% CI 0.70-0.86) · P < 0.001
Below 1 favours ramipril, above 1 favours placebo.
- Absolute difference
- 3.8 points
- NNT
- 27
Absolute difference and NNT are derived from the event rates.
Also reported: With reductions in CV death (RR 0.74), MI (RR 0.80), stroke (RR 0.68), and all-cause death (RR 0.84).
- Subtopic
- ACE inhibitor
- Design
- Multicentre double-blind placebo-controlled RCT, 2×2 factorial
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2024 HypertensionESC 2021 PreventionESC 2024 PAADACC/AHA 2025 HypertensionACC/AHA 2024 PAD
- Source
- Yusuf S, et al. N Engl J Med. 2000;342(3):145-53.doi 10.1056/NEJM200001203420301
Discussion & critique
The modest BP reduction (~3/2 mmHg) arguably too small to explain the benefit, fuelling mechanism debate; companion vitamin E arm neutral. Established ACE inhibitors for vascular protection in high-risk patients without HF or low EF.